Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls.

ABSTRACT:

Objective

To evaluate the impact of lasmiditan, an oral, centrally-penetrant, selective serotonin 1F (5-HT_1F ) receptor agonist developed for the acute treatment of migraine, on simulated driving.

Methods

Healthy adult volunteers enrolled in two randomized, placebo and active comparator-controlled, crossover studies. Study 1 (N = 90) tested lasmiditan (50-, 100-, 200-mg), alprazolam (1-mg), and placebo at 1.5 hr post-dose. Study 2 (N = 68) tested lasmiditan (100-, 200-mg), diphenhydramine (50-mg, administered 2 hr pre-assessments), and placebo at 8, 12 and 24 hr post-dose. Driving performance was assessed using a validated driving simulator employing a 100 km driving scenario. Standard deviation of lateral position (SDLP), a measure of lane position control, was t

SUBMITTER: Pearlman EM 

PROVIDER: S-EPMC7539914 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature